Observational studyAnnals of hematology2026

Real-world outcomes of inotuzumab ozogamicin treatment for adult relapsed or refractory acute lymphoblastic leukemia: a result from Korea post-marketing surveillance.

Jae-Ho Yoon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.